The spatialomics approach of TissueCypher brings precision pathology to the clinic for more personalized care of patients with BE to improve outcomes.

Our suite of highly accurate tests for melanocytic lesions of uncertain potential increases diagnostic confidence and enables better clinical management plans for patients. Learn the essentials from this comprehensive introduction by Matthew Goldberg, MD, Medical Director for Castle Biosciences.

Drs. Trotter and Sligh hosted a live Q&A session on the content discussed in this webinar. Register for free to be part of the webinar. This activity has been developed to meet the educational needs of dermatologists, nurse practitioners, physician assistants, and staff who are dedicated to the management of patients with cutaneous melanoma and cutaneous squamous cell carcinoma

Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).

The TissueCypher test may enable physicians to target EET for high-risk BE patients, while reducing unnecessary procedures in low-risk patients.

Assessing additional spatial and temporal biopsies increased the predictive accuracy, allowing for identification of most future progressors.

A risk prediction test identifies patients with non-dysplastic Barrett's esophagus who are at high risk for progression to high-grade dysplasia or cancer.